Strides Shasun gets USFDA nod for dementia drug
New Delhi: Strides Shasun said it has received approval from the US health regulator for memantine hydrochloride tablets used in the treatment of dementia.
The product will be manufactured at the company’s facility at Bengaluru and marketed by Strides Pharma Inc in the US market.
In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (USFDA) for memantine hydrochloride tablets USP, 5mg and 10 mg.
“The product will be launched immediately,” it added.
Quoting IMS sales data, Strides Shasun said the US market for memantine hydrochloride tablets USP, 5mg and 10 mg is approximately USD 60 million.
Strides Shasun stock was trading 6.25 per cent lower at Rs. 849.85 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd